We can’t show the full text here under this license. Use the link below to read it at the source.
Senescent bone marrow mesenchymal stem cells exacerbate subchondral bone sclerosis and osteoarthritis via the senescence-associated secretory phenotype
Aging bone marrow stem cells may worsen bone hardening and arthritis by releasing harmful factors
AI simplified
Abstract
A significant increase in the proportion of senescent bone marrow mesenchymal stem cells (BMSCs) was observed in subchondral bone during osteoarthritis (OA) progression.
- Senescent BMSCs in subchondral bone are associated with the activation of the (SASP).
- Conditioned medium from senescent BMSCs promotes osteogenic differentiation and increases osteogenic marker expression in normal BMSCs.
- The SASP enhances the expression of key genes Mapk8 and Mapk14 related to bone formation.
- The senolytic treatment with dasatinib and quercetin effectively clears senescent BMSCs, reduces osteocalcin levels, and inhibits subchondral bone sclerosis.
- Elimination of senescent BMSCs may alleviate OA progression.
AI simplified
Key numbers
1.149
Increase in senescent
Fold change in volume/tissue volume ratio in OA mice.
0.872
Decrease in bone volume/tissue volume ratio
Fold change in after D + Q treatment in OA mice.
Longevity & Aging